CINC News and Press, CinCor Pharma Inc.

WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat ...

Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca , while Albireo Pharma (NASDAQ: ALBO) is set to be owned by ...

Summary AstraZeneca is acquiring CinCor Pharma for $26 per share and an interesting CVR. The milestone appears easy enough to achieve although the company just had a phase 2 setback. The market values the CVR at $3.21, assuming the deal closes. The CVR pays out $10 if the milest...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Roland Magnusson / Shutterstock.com CinCor (NASDAQ: CINC ) stock is rocketing higher on Monday following news that AstraZeneca (NASDAQ: AZN ) is acquiring the company. The offer from AstraZeneca has ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday! Moving stocks this morning are acquisition deals, clinica...

AstraZeneca ( NASDAQ: AZN ) is acquiring Waltham, Ma.-based high blood pressure and kidney disease drug developer CinCor Pharma ( NASDAQ: CINC ) in a deal value of up to $1.8B. The British pharma giant said that the acquisition will bolster its cardiorenal pipeline by...

WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor. Marc de Garidel, Chief Executive Officer at CinCor, said: “We ar...

Summary US biotech stocks topped the list of dissatisfied shareholders in the worst-performing US healthcare sector, and not just because of market headwinds. Among disappointing biotech stocks, CinCor Pharma, Inc., a US biotech developer of a high blood pressure product candidate, miss...

Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that represents approximately 81-89% of the U.S. hypertension ...

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November: The CinCor management team will participate in one-on-one investor meetings during these events....